Cargando…
Novel Pathogenic Variants in LHX3, LHX4 and GLI2 Identified in Pediatric Patients With Congenital Hypopituitarism: From Variant Calling To Variant Testing
Congenital hypopituitarism (CH), septo-optic dysplasia (SOD), and holoprosencephaly (HPE) constitute an important group of structural birth defects that cause significant morbidity and life-long consequences for quality of life and care. The genetic causes are highly overlapping. As such, these diso...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090718/ http://dx.doi.org/10.1210/jendso/bvab048.1462 |
_version_ | 1783687350991192064 |
---|---|
author | Vishnopolska, Sebastian Mercogliano, María Florencia Camilletti, Maria Andrea Mortensen, Amanda Helen Braslavsky, Debora Giselle Keselman, Ana Claudia Bergada, Ignacio Marino, Roxana Marcela Ramirez, Pablo Garrido, Natalia Perez Ciaccio, Marta Di Palma, María Isabel Belgorosky, Alicia Miras, Mirta Nicola, Juan Pablo Marti, Marcelo Kitzman, Jacob Camper, Sally Ann Perez-Millan, Maria Ines |
author_facet | Vishnopolska, Sebastian Mercogliano, María Florencia Camilletti, Maria Andrea Mortensen, Amanda Helen Braslavsky, Debora Giselle Keselman, Ana Claudia Bergada, Ignacio Marino, Roxana Marcela Ramirez, Pablo Garrido, Natalia Perez Ciaccio, Marta Di Palma, María Isabel Belgorosky, Alicia Miras, Mirta Nicola, Juan Pablo Marti, Marcelo Kitzman, Jacob Camper, Sally Ann Perez-Millan, Maria Ines |
author_sort | Vishnopolska, Sebastian |
collection | PubMed |
description | Congenital hypopituitarism (CH), septo-optic dysplasia (SOD), and holoprosencephaly (HPE) constitute an important group of structural birth defects that cause significant morbidity and life-long consequences for quality of life and care. The genetic causes are highly overlapping. As such, these disorders can be considered as a spectrum of related disorders. Improved insight into genetic causes would be valuable for patients, families, and medical geneticists. Very few systematic genetic screens have been carried out for patients with CH. We implemented genetic screening using single-molecule molecular inversion probes sequencing to identify causative mutations in a set of 67 genes previously reported in CH patients and the spectrum encompassing SOD and HPE. We captured genomic DNA from 170 Argentinean pediatric patients with CH, and 54% of the patients in this cohort have craniofacial, ophthalmologic, and/or central nervous system defects. We found candidate pathogenic, likely pathogenic and variants uncertain significance (VUS) in 23% of the cases. In order to evaluate the functional consequences of VUS in LHX3, LHX4, and GLI2, we performed in-vitro functional assays to study the activity of the mutated proteins. To test LHX3/4 variants we co-transfected HEK293T cells with wild type (WT) or mutated LHX3/4 variant plasmids and luciferase reporter genes driven by the ɑGSU promoter or GH1 promoter and assayed for luciferase activity. For GLI2 functional analysis we used the cell line NIH/3T3-CG, stably transfected to express GFP under the presence of GLI2 activated form. Endogenous Gli2 was knocked out by CRISPR-Cas9 and clones were selected for absence of GFP expression upon activation of the sonic hedgehog pathway. We tested the ability of transfected WT or mutated GLI2 expression plasmids to restore GFP fluorescence. We concluded that variants LHX3:p.Pro187Ser LHX4:p.Arg84His, p.Gln100His and p.Trp204Leu and GLI2:p.1404Lfs impair activation of the reporter gene, while the LHX3:p.Leu220Met and GLI2:p.L761P have WT activity on their respective assays. Identification of disease-causing variants in CH is complicated by phenotypic variation, incomplete penetrance, and VUS. Functional testing of potentially pathogenic variants is critical to arrive at a definitive molecular diagnosis. A full catalogue of variant effects in known causative genes would be invaluable for clinicians in order to simplify the interpretation of novel variants and reduce the diagnostic odyssey that families often experience. |
format | Online Article Text |
id | pubmed-8090718 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-80907182021-05-12 Novel Pathogenic Variants in LHX3, LHX4 and GLI2 Identified in Pediatric Patients With Congenital Hypopituitarism: From Variant Calling To Variant Testing Vishnopolska, Sebastian Mercogliano, María Florencia Camilletti, Maria Andrea Mortensen, Amanda Helen Braslavsky, Debora Giselle Keselman, Ana Claudia Bergada, Ignacio Marino, Roxana Marcela Ramirez, Pablo Garrido, Natalia Perez Ciaccio, Marta Di Palma, María Isabel Belgorosky, Alicia Miras, Mirta Nicola, Juan Pablo Marti, Marcelo Kitzman, Jacob Camper, Sally Ann Perez-Millan, Maria Ines J Endocr Soc Pediatric Endocrinology Congenital hypopituitarism (CH), septo-optic dysplasia (SOD), and holoprosencephaly (HPE) constitute an important group of structural birth defects that cause significant morbidity and life-long consequences for quality of life and care. The genetic causes are highly overlapping. As such, these disorders can be considered as a spectrum of related disorders. Improved insight into genetic causes would be valuable for patients, families, and medical geneticists. Very few systematic genetic screens have been carried out for patients with CH. We implemented genetic screening using single-molecule molecular inversion probes sequencing to identify causative mutations in a set of 67 genes previously reported in CH patients and the spectrum encompassing SOD and HPE. We captured genomic DNA from 170 Argentinean pediatric patients with CH, and 54% of the patients in this cohort have craniofacial, ophthalmologic, and/or central nervous system defects. We found candidate pathogenic, likely pathogenic and variants uncertain significance (VUS) in 23% of the cases. In order to evaluate the functional consequences of VUS in LHX3, LHX4, and GLI2, we performed in-vitro functional assays to study the activity of the mutated proteins. To test LHX3/4 variants we co-transfected HEK293T cells with wild type (WT) or mutated LHX3/4 variant plasmids and luciferase reporter genes driven by the ɑGSU promoter or GH1 promoter and assayed for luciferase activity. For GLI2 functional analysis we used the cell line NIH/3T3-CG, stably transfected to express GFP under the presence of GLI2 activated form. Endogenous Gli2 was knocked out by CRISPR-Cas9 and clones were selected for absence of GFP expression upon activation of the sonic hedgehog pathway. We tested the ability of transfected WT or mutated GLI2 expression plasmids to restore GFP fluorescence. We concluded that variants LHX3:p.Pro187Ser LHX4:p.Arg84His, p.Gln100His and p.Trp204Leu and GLI2:p.1404Lfs impair activation of the reporter gene, while the LHX3:p.Leu220Met and GLI2:p.L761P have WT activity on their respective assays. Identification of disease-causing variants in CH is complicated by phenotypic variation, incomplete penetrance, and VUS. Functional testing of potentially pathogenic variants is critical to arrive at a definitive molecular diagnosis. A full catalogue of variant effects in known causative genes would be invaluable for clinicians in order to simplify the interpretation of novel variants and reduce the diagnostic odyssey that families often experience. Oxford University Press 2021-05-03 /pmc/articles/PMC8090718/ http://dx.doi.org/10.1210/jendso/bvab048.1462 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Pediatric Endocrinology Vishnopolska, Sebastian Mercogliano, María Florencia Camilletti, Maria Andrea Mortensen, Amanda Helen Braslavsky, Debora Giselle Keselman, Ana Claudia Bergada, Ignacio Marino, Roxana Marcela Ramirez, Pablo Garrido, Natalia Perez Ciaccio, Marta Di Palma, María Isabel Belgorosky, Alicia Miras, Mirta Nicola, Juan Pablo Marti, Marcelo Kitzman, Jacob Camper, Sally Ann Perez-Millan, Maria Ines Novel Pathogenic Variants in LHX3, LHX4 and GLI2 Identified in Pediatric Patients With Congenital Hypopituitarism: From Variant Calling To Variant Testing |
title | Novel Pathogenic Variants in LHX3, LHX4 and GLI2 Identified in Pediatric Patients With Congenital Hypopituitarism: From Variant Calling To Variant Testing |
title_full | Novel Pathogenic Variants in LHX3, LHX4 and GLI2 Identified in Pediatric Patients With Congenital Hypopituitarism: From Variant Calling To Variant Testing |
title_fullStr | Novel Pathogenic Variants in LHX3, LHX4 and GLI2 Identified in Pediatric Patients With Congenital Hypopituitarism: From Variant Calling To Variant Testing |
title_full_unstemmed | Novel Pathogenic Variants in LHX3, LHX4 and GLI2 Identified in Pediatric Patients With Congenital Hypopituitarism: From Variant Calling To Variant Testing |
title_short | Novel Pathogenic Variants in LHX3, LHX4 and GLI2 Identified in Pediatric Patients With Congenital Hypopituitarism: From Variant Calling To Variant Testing |
title_sort | novel pathogenic variants in lhx3, lhx4 and gli2 identified in pediatric patients with congenital hypopituitarism: from variant calling to variant testing |
topic | Pediatric Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090718/ http://dx.doi.org/10.1210/jendso/bvab048.1462 |
work_keys_str_mv | AT vishnopolskasebastian novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT mercoglianomariaflorencia novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT camillettimariaandrea novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT mortensenamandahelen novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT braslavskydeboragiselle novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT keselmananaclaudia novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT bergadaignacio novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT marinoroxanamarcela novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT ramirezpablo novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT garridonataliaperez novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT ciacciomarta novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT dipalmamariaisabel novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT belgoroskyalicia novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT mirasmirta novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT nicolajuanpablo novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT martimarcelo novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT kitzmanjacob novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT campersallyann novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting AT perezmillanmariaines novelpathogenicvariantsinlhx3lhx4andgli2identifiedinpediatricpatientswithcongenitalhypopituitarismfromvariantcallingtovarianttesting |